Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) COO Jonathan Young sold 607 shares of the stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $44.88, for a total transaction of $27,242.16. Following the sale, the chief operating officer now owns 200,540 shares of the company's stock, valued at $9,000,235.20. This trade represents a 0.30 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Jonathan Young also recently made the following trade(s):
- On Tuesday, March 4th, Jonathan Young sold 50,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $44.86, for a total transaction of $2,243,000.00.
- On Monday, February 3rd, Jonathan Young sold 10,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $53.81, for a total transaction of $538,100.00.
- On Thursday, January 2nd, Jonathan Young sold 10,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $28.03, for a total transaction of $280,300.00.
Akero Therapeutics Stock Performance
Shares of AKRO opened at $44.15 on Friday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 17.25 and a current ratio of 17.25. Akero Therapeutics, Inc. has a twelve month low of $17.86 and a twelve month high of $58.40. The firm's 50 day moving average price is $42.10 and its two-hundred day moving average price is $33.79. The firm has a market cap of $3.52 billion, a P/E ratio of -11.77 and a beta of -0.19.
Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last announced its quarterly earnings results on Friday, February 28th. The company reported ($0.99) earnings per share for the quarter, missing analysts' consensus estimates of ($0.98) by ($0.01). On average, analysts forecast that Akero Therapeutics, Inc. will post -3.99 EPS for the current fiscal year.
Analysts Set New Price Targets
Several equities research analysts have recently commented on the stock. Canaccord Genuity Group lifted their price target on shares of Akero Therapeutics from $56.00 to $73.00 and gave the stock a "buy" rating in a research report on Tuesday, January 28th. Citigroup lifted their price target on shares of Akero Therapeutics from $65.00 to $80.00 and gave the stock a "buy" rating in a research report on Tuesday, January 28th. Bank of America upgraded shares of Akero Therapeutics from a "neutral" rating to a "buy" rating and lifted their price target for the stock from $35.00 to $63.00 in a research report on Thursday, January 30th. HC Wainwright lifted their price target on shares of Akero Therapeutics from $72.00 to $75.00 and gave the stock a "buy" rating in a research report on Monday, March 3rd. Finally, Morgan Stanley reissued an "overweight" rating on shares of Akero Therapeutics in a research note on Sunday, March 2nd. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $76.29.
Get Our Latest Stock Report on Akero Therapeutics
Institutional Trading of Akero Therapeutics
A number of institutional investors have recently made changes to their positions in the business. GF Fund Management CO. LTD. bought a new stake in shares of Akero Therapeutics in the fourth quarter worth $41,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Akero Therapeutics by 18.3% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 71,451 shares of the company's stock worth $1,988,000 after purchasing an additional 11,035 shares in the last quarter. Woodline Partners LP lifted its position in shares of Akero Therapeutics by 29.9% in the fourth quarter. Woodline Partners LP now owns 379,967 shares of the company's stock worth $10,571,000 after purchasing an additional 87,499 shares in the last quarter. Two Sigma Advisers LP lifted its position in shares of Akero Therapeutics by 195.7% in the fourth quarter. Two Sigma Advisers LP now owns 41,100 shares of the company's stock worth $1,143,000 after purchasing an additional 27,200 shares in the last quarter. Finally, Two Sigma Investments LP lifted its position in shares of Akero Therapeutics by 43.3% in the fourth quarter. Two Sigma Investments LP now owns 127,320 shares of the company's stock worth $3,542,000 after purchasing an additional 38,500 shares in the last quarter.
Akero Therapeutics Company Profile
(
Get Free Report)
Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
